Hydrogen vs Methane vs H2S SIBO: Know Your Type

Not all SIBO is the same — and treating the wrong type with the wrong protocol is one of the most common reasons people cycle through treatments without improving. SIBO is now understood to encompass three distinct subtypes defined by the gases produced: hydrogen (H2), methane (CH4), and hydrogen sulfide (H2S). Each is driven by different microorganisms living in different niches of the gut, each produces its own characteristic symptom signature, and critically, each responds to different treatment strategies. A methane-dominant patient treated only with rifaximin — the standard SIBO antibiotic — will almost certainly relapse because rifaximin does not target the archaea responsible for methane production. Understanding your type is not academic; it directly determines whether your treatment will work.

Hydrogen SIBO: The Most Common Presentation

Hydrogen-dominant SIBO, sometimes called classic SIBO, is caused by an overgrowth of hydrogen-producing bacteria in the small intestine. The most common offenders include species of Escherichia, Klebsiella, Proteus, Bacteroides, and various Clostridium species — organisms that ferment undigested carbohydrates and produce hydrogen gas as a byproduct. In a healthy gut, most fermentation occurs in the large intestine where it belongs; in SIBO, it happens too far upstream in the small bowel, causing gas to accumulate before it can be properly managed. The hallmark symptom of hydrogen-dominant SIBO is diarrhea or loose stools, often occurring within 1-2 hours of eating, especially after consuming high-FODMAP or high-starch foods. Bloating and abdominal distension are nearly universal. Many patients also experience nausea, abdominal cramping, urgency, and significant fatigue after meals. The mechanism is well understood: the rapidly produced hydrogen gas distends the bowel, stimulates intestinal motility, and draws fluid into the intestinal lumen — all of which produce diarrhea and pain. On a lactulose or glucose breath test, hydrogen SIBO produces an early rise in hydrogen gas (typically defined as a rise of 20 ppm above baseline within the first 90 minutes for lactulose, or any rise for glucose). Rifaximin at 550 mg three times daily for 14 days is the evidence-supported first-line pharmaceutical treatment.

Methane SIBO and IMO: The Constipation Driver

Methane-dominant SIBO has been officially reclassified by leading researchers as IMO — intestinal methanogen overgrowth — to reflect the fact that the methane-producing organisms are archaea, not bacteria. The primary culprit is Methanobrevibacter smithii, an archaeon that does not produce hydrogen itself but instead consumes the hydrogen produced by bacteria and converts it to methane. This cross-feeding relationship means that archaea are often found downstream of hydrogen-producing bacteria, and elevated methane on a breath test frequently indicates elevated hydrogen-producing bacteria as well — even when the breath test shows methane as the predominant gas. The physiological effect of methane on the gut is dramatically different from hydrogen. Methane is not a fermentation byproduct that distends the bowel in the same way; instead, it appears to directly slow intestinal transit. Research by Pimentel and colleagues demonstrated that methane gas infused into the intestines of laboratory animals reduces intestinal transit time by nearly 59% — a finding that explains why the defining symptom of IMO is constipation rather than diarrhea. Patients with methane-dominant SIBO often describe straining, incomplete evacuation, hard pellet-like stools, and a dramatic improvement in bowel frequency during or after antibiotic treatment. Bloating and distension are typically less meal-triggered than in hydrogen SIBO and may be more persistent and diffuse. Standard breath testing will show elevated methane gas (typically defined as any reading above 10 ppm at any point during the test). Treatment requires covering archaea specifically: the standard pharmaceutical protocol is rifaximin plus neomycin, while the herbal approach commonly uses allicin (stabilized garlic extract) as the anti-archaeal centerpiece.

An important nuance: because M. smithii consumes hydrogen, patients with high methane levels may actually show low or normal hydrogen on their breath test despite having significant bacterial overgrowth. The bacteria are producing hydrogen, but the archaea are immediately consuming it before it can be exhaled. This can lead to under-diagnosis of the bacterial component and is one reason IMO is often harder to fully eradicate — treating only the archaea leaves the underlying hydrogen-producing bacteria in place.

Hydrogen Sulfide SIBO (ISO): The Most Recently Recognized Type

Hydrogen sulfide overgrowth — now termed ISO (intestinal sulfide overgrowth) in emerging research — is the third and most recently characterized SIBO subtype. It is produced by sulfate-reducing bacteria including Desulfovibrio species, Bilophila wadsworthia, and others that use sulfate as a terminal electron acceptor rather than oxygen. These bacteria are particularly difficult to detect because hydrogen sulfide gas is not measured by standard SIBO breath tests. Most commercial breath test panels measure only hydrogen and methane; H2S is not detected by the same electrochemical sensors. This means that a significant number of patients with symptoms consistent with SIBO — particularly those with diarrhea and a history of sulfur-related symptoms — may test completely negative on standard breath tests despite having genuine sulfide overgrowth. A specialized breath test measuring all three gases (the TrioSmart test from Gemelli Biotech being the most widely used example) is required to detect hydrogen sulfide. Symptom-wise, hydrogen sulfide SIBO often presents like hydrogen SIBO — with diarrhea, urgency, and bloating — but with additional telltale features: stools that float (sulfide causes gas to be trapped in stool), a rotten egg or sulfurous odor to flatulence and sometimes stools, and symptoms that worsen with high-sulfur foods (eggs, cruciferous vegetables, garlic, meat). Some patients also experience fatigue and neurological symptoms that may relate to hydrogen sulfide's known inhibitory effects on cytochrome c oxidase (the same mechanism by which high-dose H2S is toxic). Treatment for hydrogen sulfide SIBO is less standardized than for the other two types. A low-sulfur diet (reducing sulfate from foods and drinks, including cruciferous vegetables, eggs, alcohol, and sulfite-preserved foods) is often the first dietary intervention. Bismuth subsalicylate (Pepto-Bismol) is frequently used because bismuth binds to hydrogen sulfide and reduces its concentration in the gut. Some clinicians use rifaximin, metronidazole, or herbal antimicrobials with activity against anaerobes.

Breath Test Interpretation by Type

Breath testing is the primary non-invasive diagnostic tool for all three SIBO types. Understanding how each type appears on testing is important for accurate diagnosis and for interpreting results. For hydrogen SIBO, the North American Consensus criteria define a positive test as a rise in hydrogen of 20 ppm or more above baseline within the first 90 minutes on a lactulose breath test, or any rise of 20 ppm on a glucose breath test. For methane (IMO), a positive test is defined as any methane reading of 10 ppm or higher at any point during the test — the threshold is lower than for hydrogen, and the timing of the peak is less important. For hydrogen sulfide (ISO), no universally agreed-upon positivity threshold has been established as of 2026, but many clinicians use any detectable H2S above 2-3 ppm as clinically significant in symptomatic patients. An important limitation of breath testing applies to all three types: the tests measure exhaled gas, not intestinal gas directly, and various factors — preparation diet, intestinal transit speed, oral bacteria, and testing methodology — all affect results. False negatives occur when organisms don't produce enough gas to be detectable in breath, and false positives can occur when colonic fermentation is rapid enough to produce early gas rises. Despite these limitations, breath testing remains the most practical diagnostic approach for most patients, as the alternative — jejunal aspirate culture — requires endoscopy with sterile technique and is rarely performed outside research settings.

Can You Have Multiple Types Simultaneously?

Yes — and this is more common than many patients realize. Because M. smithii (the methane-producing archaeon) feeds on hydrogen, patients with methane-dominant SIBO almost always have hydrogen-producing bacteria as well. A breath test showing primarily methane does not mean no hydrogen-producing bacteria are present; it may mean the archaea are consuming the hydrogen before it can be detected. The practical implication is that IMO almost always requires treating both the archaea (with allicin or neomycin) and the underlying bacteria (with rifaximin or oregano oil) simultaneously. Mixed hydrogen-methane presentations, where both gases are elevated, are common and typically indicate a more established overgrowth with both bacterial and archaeal components. These patients generally need combination therapy from the start. Hydrogen-methane-sulfide triple-positive presentations are less common but are increasingly being detected as three-gas testing becomes more available. These complex cases typically require more prolonged and layered treatment approaches and benefit most from working with an experienced SIBO specialist who can customize the protocol. Mixed types also affect prognosis: methane-dominant and mixed-type SIBO patients tend to have lower eradication rates and higher relapse rates than pure hydrogen SIBO, partly because treating the archaeal component is inherently more difficult.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.